Opportunistic virus DNA levels after pediatric stem cell transplantation: Serostatus matching, anti-thymocyte globulin, and total body irradiation are additive risk factors

Transplant Infectious Disease

Volumn 13, Issue 2, 2011, Pages 122-130

  Kullberg Lindh, C ^a   Mellgren, K ^a   Friman, V ^a   Fasth, A ^a   Ascher, H ^a,b   Nilsson, S ^c   Lindh, M ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Adenovirus; CMV; Cytomegalovirus; EBV; Epstein Barr virus; HHV6; Human herpesvirus 6; Pediatric; Real time PCR; SCT; Stem cell transplant

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOMEGALOVIRUS ANTIBODY; ETOPOSIDE; FLUDARABINE; FOSCARNET SODIUM; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHOTREXATE; TACROLIMUS; THYMOCYTE ANTIBODY; VALACICLOVIR; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ADENOVIRUS; ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INFECTION RISK; MALE; MYELOABLATIVE CONDITIONING; OPPORTUNISTIC INFECTION; PNEUMOCYSTOSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; SEROLOGY; STEM CELL TRANSPLANTATION; VIREMIA; VIRUS INFECTION; WHOLE BODY RADIATION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTIBODIES, VIRAL; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DNA VIRUS INFECTIONS; DNA VIRUSES; DNA, VIRAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; VIREMIA; WHOLE-BODY IRRADIATION;

EID: 79953332138     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2010.00564.x     Document Type: Article

References (43)

1. Boeckh M, Erard V, Zerr D, Englund J. Emerging viral infections after hematopoietic cell transplantation. Pediatr Transplant 2005; 9 (Suppl 7): 48-54.
2. Walls T, Hawrami K, Ushiro-Lumb I, Shingadia D, Saha V, Shankar AG. Adenovirus infection after pediatric bone marrow transplantation: is treatment always necessary? Clin Infect Dis 2005; 40 (9): 1244-1249.
3. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986; 153 (3): 478-488.
4. Broers AE, van Der Holt R, van Esser JW, et al. Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation. Blood 2000; 95 (7): 2240-2245.
5. Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19 (3): 241-248.
6. Gross TG, Loechelt BJ. Epstein-Barr virus associated disease following blood or marrow transplant. Pediatr Transplant 2003; 7 (Suppl 3): 44-50.
7. Runde V, Ross S, Trenschel R, et al. Adenoviral infection after allogeneic stem cell transplantation (SCT): report on 130 patients from a single SCT unit involved in a prospective multi center surveillance study. Bone Marrow Transplant 2001; 28 (1): 51-57.
8. Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994; 169 (4): 775-781.
9. Hoffman JA, Shah AJ, Ross LA, Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001; 7 (7): 388-394.
10. Baldwin A, Kingman H, Darville M, et al. Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation. Bone Marrow Transplant 2000; 26 (12): 1333-1338.
11. Asano-Mori Y, Oshima K, Sakata-Yanagimoto M, et al. High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36 (9): 813-819.
12. Bordon V, Bravo S, Van Renterghem L, et al. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Transpl Infect Dis 2008; 10 (1): 19-23.
13. Leruez-Ville M, Ouachee M, Delarue R, et al. Monitoring cytomegalovirus infection in adult and pediatric bone marrow transplant recipients by a real-time PCR assay performed with blood plasma. J Clin Microbiol 2003; 41 (5): 2040-2046.
14. Haastrup E, Muller K, Baekgaard H, Heilmann C. Cytomegalovirus infection after allogeneic stem cell transplant in children. Pediatr Transplant 2005; 9 (6): 734-740.
15. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol 2003; 21 (7): 1352-1358.
16. Aalto SM, Juvonen E, Tarkkanen J, et al. Lymphoproliferative disease after allogeneic stem cell transplantation - pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum. J Clin Virol 2003; 28 (3): 275-283.
17. Gross TG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23 (3): 251-258.
18. Collins MH, Montone KT, Leahey AM, et al. Post-transplant lymphoproliferative disease in children. Pediatr Transplant 2001; 5 (4): 250-257.
19. Ocheni S, Kroeger N, Zabelina T, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008; 42 (3): 181-186.
20. Wingard JR. Opportunistic infections after blood and marrow transplantation. Transpl Infect Dis 1999; 1 (1): 3-20.
21. Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol 2000; 53 (4): 248-254.
22. Schafer H, Berger C, Aepinus C, et al. Molecular pathogenesis of Epstein-Barr virus associated posttransplant lymphomas: new insights through latent membrane protein 1 fingerprinting. Transplantation 2001; 72 (3): 492-496.
23. Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003; 13 (3): 155-171.
24. Hale GA, Heslop HE, Krance RA, et al. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant 1999; 23 (3): 277-282.
25. Heim A, Ebnet C, Harste G, Pring-Akerblom P. Rapid and quantitative detection of human adenovirus DNA by real-time PCR. J Med Virol 2003; 70 (2): 228-239.
26. Lion T, Baumgartinger R, Watzinger F, et al. Molecular monitoring of adenovirus in peripheral blood after allogeneic bone marrow transplantation permits early diagnosis of disseminated disease. Blood 2003; 102 (3): 1114-1120.
27. Levy JA, Ferro F, Greenspan D, Lennette ET. Frequent isolation of HHV-6 from saliva and high seroprevalence of the virus in the population. Lancet 1990; 335 (8697): 1047-1050.
28. Savolainen H, Lautenschlager I, Piiparinen H, Saarinen-Pihkala U, Hovi L, Vettenranta K. Human herpesvirus-6 and -7 in pediatric stem cell transplantation. Pediatr Blood Cancer 2005; 45 (6): 820-825.
29. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34 (8): 1094-1097.
30. Kalpoe JS, Kroes AC, de Jong MD, et al. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol 2004; 42 (4): 1498-1504.
31. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94 (7): 2208-2216.
32. Apperley J, Carreras E, Gluckman E, Gratwohl A, Messzi T, (eds). The EBMT-ESH Handbook: Haematopoietic Stem Cell Transplantation (5th edn). Genoa, Italy: EBMT-ESH, Forum Services, 2008: 218-228.
33. Dahl H, Linde A, Sundqvist VA, Wahren B. An enzyme-linked immunosorbent assay for IgG antibodies to human herpes virus 6. J Virol Methods 1990; 29 (3): 313-323.
34. Kullberg-Lindh C, Olofsson S, Brune M, Lindh M. Comparison of serum and whole blood levels of cytomegalovirus and Epstein-Barr virus DNA. Transpl Infect Dis 2008; 10 (5): 308-315.
35. Niesters HG, van Esser J, Fries E, Wolthers KC, Cornelissen J, Osterhaus AD. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000; 38 (2): 712-715.
36. Collot S, Petit B, Bordessoule D, et al. Real-time PCR for quantification of human herpesvirus 6 DNA from lymph nodes and saliva. J Clin Microbiol 2002; 40 (7): 2445-2451.
37. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003; 102 (13): 4255-4260.
38. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998; 21 (6): 597-605.
39. Ringden O, Schaffer M, Le Blanc K, et al. Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers? Biol Blood Marrow Transplant 2004; 10 (2): 128-134.
40. Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008; 111 (11): 5403-5410.
41. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98 (4): 972-978.
42. Yamane A, Mori T, Suzuki S, et al. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant 2007; 13 (1): 100-106.
43. Echavarria M, Forman M, van Tol MJ, Vossen JM, Charache P, Kroes AC. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet 2001; 358 (9279): 384-385.